Gangnon Ronald E, Sprague Brian L, Stout Natasha K, Alagoz Oguz, Weedon-Fekjær Harald, Holford Theodore R, Trentham-Dietz Amy
Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin. Department of Population Health Sciences, University of Wisconsin, Madison, Wisconsin. Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin.
Department of Surgery and Vermont Cancer Center, University of Vermont, Burlington, Vermont.
Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):905-12. doi: 10.1158/1055-9965.EPI-14-1286. Epub 2015 Mar 18.
The impact of screening mammography on breast cancer incidence is difficult to disentangle from cohort- and age-related effects on incidence.
We developed an age-period-cohort model of ductal carcinoma in situ (DCIS) and invasive breast cancer incidence in U.S. females using cancer registry data. Five functions were included in the model to estimate stage-specific effects for age, premenopausal birth cohorts, postmenopausal birth cohorts, period (for all years of diagnosis), and a mammography period effect limited to women ages ≥ 40 years after 1982. Incidence with and without the mammography period effect was calculated.
More recent birth cohorts have elevated underlying risk compared with earlier cohorts for both pre- and postmenopausal women. Comparing models with and without the mammography period effect showed that overall breast cancer incidence would have been 23.1% lower in the absence of mammography in 2010 (95% confidence intervals, 18.8-27.4), including 14.7% (9.5-19.3) lower for invasive breast cancer and 54.5% (47.4-59.6) lower for DCIS. Incidence of distant-staged breast cancer in 2010 would have been 29.0% (13.1-48.1) greater in the absence of mammography screening.
Mammography contributes to markedly elevated rates of DCIS and early-stage invasive cancers, but also contributes to substantial reductions in the incidence of metastatic breast cancer.
Mammography is an important tool for reducing the burden of breast cancer, but future work is needed to identify risk factors accounting for increasing underlying incidence and to distinguish between indolent and potentially lethal early-stage breast cancers that are detected via mammography.
乳腺钼靶筛查对乳腺癌发病率的影响难以与队列效应和年龄相关效应区分开来。
我们利用癌症登记数据建立了美国女性原位导管癌(DCIS)和浸润性乳腺癌发病率的年龄-时期-队列模型。该模型包含五个函数,用于估计年龄、绝经前出生队列、绝经后出生队列、时期(所有诊断年份)以及仅限于1982年后年龄≥40岁女性的钼靶检查时期效应的阶段特异性效应。计算了有和没有钼靶检查时期效应的发病率。
与早期队列相比,无论是绝经前还是绝经后女性,较近期出生队列的潜在风险都有所升高。比较有和没有钼靶检查时期效应的模型表明,2010年若没有钼靶检查,总体乳腺癌发病率将降低23.1%(95%置信区间,18.8 - 27.4),其中浸润性乳腺癌降低14.7%(9.5 - 19.3),DCIS降低54.5%(47.4 - 59.6)。2010年远处分期乳腺癌的发病率若没有钼靶筛查将高出29.0%(13.1 - 48.1)。
乳腺钼靶检查导致DCIS和早期浸润性癌症的发病率显著升高,但也有助于大幅降低转移性乳腺癌的发病率。
乳腺钼靶检查是减轻乳腺癌负担的重要工具,但未来需要开展工作,以确定导致潜在发病率上升的风险因素,并区分通过钼靶检查发现的惰性和潜在致命性早期乳腺癌。